Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to antibody or antibody fragment or immunoglobulin;...
Patent
1998-11-03
2000-06-20
Dees, Jose' G.
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to antibody or antibody fragment or immunoglobulin;...
424 111, 424 165, A61K 5100, A61M 3614
Patent
active
060774991
ABSTRACT:
The invention provides compositions, methods and kits for effecting therapy of a tumor in a patient. The compositions comprise (A) a first conjugate comprising a targeting moiety, a first member of a binding pair, and a first therapeutic agent, wherein the targeting moiety selectively binds to a marker substance produced by or associated with the tumor; (B) optionally, a clearing composition; and (C) a second conjugate comprising a complementary member of the binding pair and a second therapeutic agent, wherein the second therapeutic agent is the same as or different from the first therapeutic agent. The methods comprise sequentially administering (A), (B), and (C) to a patient. The kits comprise (A), (B), and (C) in separate containers.
REFERENCES:
patent: 4624846 (1986-11-01), Goldenberg
patent: 4818684 (1989-04-01), Edelman et al.
patent: 5283342 (1994-02-01), Gustavson et al.
patent: 5420105 (1995-05-01), Gustavson et al.
patent: 5474772 (1995-12-01), Maddock
patent: 5482698 (1996-01-01), Griffiths
patent: 5525338 (1996-06-01), Goldenberg
patent: 5621002 (1997-04-01), Bosslet et al.
patent: 5632990 (1997-05-01), Bagshawe et al.
patent: 5683694 (1997-11-01), Bagshawe et al.
patent: 5846741 (1998-12-01), Griffiths et al.
Senter et al, Cancer Research, 56, 1471-1474, "The Role of Rat Serum Carboxylesterase in the Activation of Paclitaxel and Camplothecin Prodrugs", Apr. 1996.
Meyer et al, Bioconjugate Chem., 6, 440-446, "Site Specific Prodrug Activation by Antibody-B-Lactamase Conjugates: Preclinical Investigation of the Efficacy & Toxicity of Doxorubicin Delivered by Antibody Directed Catalysts", 1995.
Vitols et al, Cancer Research, 55, 478-481, "Methotrexate-L-phenylalanine: Optimization of Methotrexate prodrug for activation by carboxypeptidas A-Monoclonal Antibody Conjugate", Feb. 1995.
Rodrigues et al, Cancer Research, 55, 63-70, "Development of a Humanized Disulfide Stabilize Anti-p185-Herz FV-B-Lactamase Fusion Protein for activation of a cephalosporin doxorubicin prodrug", Jan. 1995.
Sahin et al, Cancer Research, 50, 6944-6948, "Specific Activation of the prodrug mitomyain phosphate by a bispecific AntiCD30/Anti Alkaline phosphatase monoclonal antibody", Nov. 1990.
Goodman et al, The Pharmacological Basis of Therapeutics, 6.sup.th Edition, pp. 1252-1300, Macmillan Publishing Co; New York, 1980.
O'Donoghue et al., J. Nucl. Med., 36:1902-1909 (Oct. 1995).
Griffiths Gary L.
Hansen Hans J.
Dees Jos,e G.
Immunomedics Inc.
Jones Dameron
LandOfFree
Targeted combination immunotherapy of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Targeted combination immunotherapy of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeted combination immunotherapy of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1849707